• Genome-Wide Profile of Pleural Mesothelioma versus Parietal and Visceral Pleura : The emerging Gene Portrait of the Mesothelioma Phenotype 

      Olsen, Karina Standahl; Røe, Oluf Dimitri; Anderssen, Endre; Helge, Eli; Pettersen, Caroline Hild; Sandeck, H; Haaverstad, Rune; Lundgren, Steinar; Larsson, Erik (Journal article; Tidsskriftartikkel; Peer reviewed, 2009)
    • Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer 

      Nøst, Therese Haugdahl; Skogholt, Anne Heidi; Urbarova, Ilona Halva; Mjelle, Robin; Paulsen, Erna-Elise; Dønnem, Tom; Andersen, Sigve; Markaki, Maria; Røe, Oluf Dimitri; Johansson, Mikael; Johansson, Mattias; Grønberg, Bjørn Henning; Sandanger, Torkjel M; Sætrom, Pål (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-07)
      Lung cancer (LC) incidence is increasing globally and altered levels of microRNAs (miRNAs) in blood may contribute to identification of individuals with LC. We identified miRNAs differentially expressed in peripheral blood at LC diagnosis and evaluated, in pre-diagnostic blood specimens, how long before diagnosis expression changes of such candidate miRNAs could be detected. We identified upregulated ...
    • Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma 

      Røe, Oluf Dimitri; Szulkin, Adam; Anderssen, Endre; Flatberg, Arnar; Sandeck, Helmut; Amundsen, Tore; Erlandsen, Sten Even; Dobra, Katalin; Sundstrøm, Stein Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2012)
      Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the first time a genome-wide profile of acquired resistance in the tumour from an exceptional case with advanced pleural ...